Search Results - "Rogers, Sherise C"

Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes by Reams, R. Renee, Odedina, Folakemi T., Carpten, John D., Redda, Kinfe, Stern, Mariana C., Krieger, Janice L., Aparicio, Jose, Hensel, Brooke, Askins, Nissa, Abreu, Andre, Adams, Angela, Agyare, Edward, Ali, Jamel, Allen, John M., Aló, Richard, Baezconde-Garbanati, Lourdes, Brant, Jason, Brown, Clyde P., Buxbaum, Sarah G., Cohen, Pinchas, Cozen, Wendy, Ezenwa, Miriam O., Falzarano, Sara, Fillingim, Roger B., Flores-Rozas, Hernan, Fredenburg, Kristianna M., George, Thomas, Han, Bo, Huang, Yong, Hughes Halbert, Chanita, Kiros, Gebre-Egziabher, Lamango, Nazarius S., Lee, Ji-Hyun, Lyon, Debra E., Mitchell, Duane A., Mochona, Bereket, Nieva, Jorge J., Offringa, Ite A., Okunieff, Paul, Parker, Alexander, Rhie, Suhn K., Richey, Joyce M., Rogers, Sherise C., Salhia, Bodour, Schmittgen, Thomas D., Segal, Richard, Setiawan, Veronica W., Smith, Ukamaka, Su, Li-Ming, Suther, Sandra, Trevino, Jose, Velazquez-Villarreal, Enrique I., Webb, Fern J., Wu, Anna H., Yao, Yingwei, Wilkie, Diana J.

“…Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE2) Health Equity Center is a triad partnership committed to increasing…”
Get full text

Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies by Allen, John M, Awunti, MegCholack, Guo, Yi, Bian, Jiang, Rogers, Sherise C, Scarton, Lisa, DeRemer, David L, Wilkie, Diana J

“…Supportive care medication use differences may contribute to racial disparities observed in health-related quality of life in patients with pancreatic cancer…”
Get full text

Analysis of pancreatic cancer treatment and survival disparities in Florida throughout the Covid-19 pandemic by Telisnor, Guettchina, Lim, Alexander, Zhang, Zhongyue, Lou, XiangYang, Nassour, Ibrahim, Salloum, Ramzi G., Rogers, Sherise C.

“…Pancreatic ductal adenocarcinoma (PDAC) is currently the third-leading cause of cancer-related death in the United States. African Americans (AAs) with PDAC…”
Get full text

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans by Telisnor, Guettchina, DeRemer, David L., Frimpong, Esther, Agyare, Edward, Allen, John, Ricks-Santi, Luisel, Han, Bo, George, Thomas, Rogers, Sherise C.

“…Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite…”
Get full text

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis by Rogers, Sherise C., Garcia, Christine A., Wu, Shenhong

“…A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse…”
Get full text

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study by Gera, Kriti, Kahramangil, Doga, Fenton, Graeme A, Martir, Daniela, Rodriguez, Diana N, Ijaz, Zohaib, Lin, Rick Y, Rogers, Sherise C, Ramnaraign, Brian H, George, Thomas J, Hong, Young-Rock, Hughes, Steven J, Nassour, Ibrahim, Sahin, Ilyas

“…Gallbladder carcinoma (GBC) is a rare, aggressive malignancy comprising 0.5% of gastrointestinal cancers. It has poor survival outcomes due to its insidious…”
Get full text

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma by Singhal, Ruchi, Rogers, Sherise C, Lee, Ji-Hyun, Ramnaraign, Brian, Sahin, Ilyas, Fabregas, Jesus C, Thomas, Ryan M, Hughes, Steven J, Nassour, Ibrahim, Hitchcock, Kathryn, Russell, Karen, Kayaleh, Omar, Turk, Anita, Zlotecki, Robert, DeRemer, David L, George, Thomas J

“…For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical…”
Get full text

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial by Ramnaraign, Brian H, Lee, Ji-Hyun, Ali, Azka, Rogers, Sherise C, Fabregas, Jesus C, Thomas, Ryan M, Allegra, Carmen J, Sahin, Ilyas, DeRemer, David L, George, Thomas J, Chatzkel, Jonathan A

“…Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the…”
Get full text

Chemotherapy is associated with improved survival in a national cohort of stage IV pancreatic adenosquamous carcinoma by Altshuler, Ellery, Riner, Andrea N, Herremans, Kelly M, George, Thomas J, Rogers, Sherise C, Paniccia, Alessandro, Hughes, Steven J, Fabregas, Jesus C, Nassour, Ibrahim

“…Pancreatic adenosquamous carcinoma (PASC) is a rare cancer that often presents with advanced disease and carries a grim prognosis. PASC is defined by the…”
Get full text

Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis by Ozer, Muhammet, Goksu, Suleyman Yasin, Lin, Rick Y, Ayasun, Ruveyda, Kahramangil, Doga, Rogers, Sherise C, Fabregas, Jesus C, Ramnaraign, Brian H, George, Thomas J, Feely, Michael, Cabrera, Roniel, Duarte, Sergio, Zarrinpar, Ali, Sahin, Ilyas

“…Advanced hepatocellular carcinoma (HCC) generally has a dismal prognosis. Bone metastases from HCC are infrequent, with a poorer prognosis. However, the…”
Get full text

Impact of COVID-19 pandemic on pancreatic cancer disparities and outcomes in Florida by Lim, Alexander, Telisnor, Guettchina, Zhang, Zhongyue, Lou, XiangYang, Nassour, Ibrahim, Salloum, Ramzi, Rogers, Sherise C.

“…667 Background: Pancreatic cancer (PDAC) is the third-leading cause of cancer death in the United States. Florida had a high infection rate with several peaks…”
Get full text

Influence of clinical and tumor characteristics on survival in patients with hepatocellular carcinoma with bone metastasis by Ozer, Muhammet, Goksu, Suleyman Yasin, Fabregas, Jesus C., Ramnaraign, Brian Hemendra, Rogers, Sherise C., George, Thomas J., Sahin, Ilyas

“…525 Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the incidence of liver cancer is rapidly rising in the…”
Get full text

Clinical validation of Northstar response: A novel methylated ctDNA therapy response monitoring assay in patients with advanced gastrointestinal cancers by Sahin, Ilyas, Kahramangil, Doga, Kim, George P., Rogers, Sherise C., Ramnaraign, Brian Hemendra, Manda, Pravalika, Varga, Matthew Gordon, Palmer, Gary A., Ye, Patrick Peiyong, George, Thomas J.

“…e16000 Background: Circulating tumor DNA (ctDNA) offers a non-invasive method to comprehensively assess tumors. While most assays for therapy response…”
Get full text

A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies by Ramnaraign, Brian Hemendra, Lee, Ji-Hyun, Sahin, Ilyas, Rogers, Sherise C., Thomas, Ryan M., Allegra, Carmen J., DeRemer, David L., George, Thomas J., Chatzkel, Jonathan Alexander

“…TPS715 Background: Checkpoint inhibitor therapy represents a significant advance in cancer care however it is not an effective intervention in the treatment of…”
Get full text

Clinical validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay in patients with advanced GI cancer undergoing active treatment by Sahin, Ilyas, Kahramangil, Doga, Rogers, Sherise C., Ramnaraign, Brian Hemendra, Manda, Pravalika, Varga, Matthew Gordon, Palmer, Gary A., Ye, Patrick Peiyong, George, Thomas J.

“…756 Background: ctDNA is a non-invasive way to holistically assess the tumor. Several assays developed for therapy response monitoring rely on variant allele…”
Get full text

Impact of metastasectomy for extrahepatic disease in stage IV colon cancer: A retrospective cohort NCDB analysis by Fabregas, Jesus C., Sahin, Ilyas, Rogers, Sherise C., Ramnaraign, Brian Hemendra, Nassour, Ibrahim, Hughes, Steven J., George, Thomas J.

“…e15548 Background: Stage IV colon cancer has a dismal prognosis with a 5-yr survival rate of only 14%. The role of liver metastasectomy is well established…”
Get full text

Does severity of periodontal disease influence the risk of developing gastrointestinal malignancies? by Iqbal, Umar, Mendes Duarte, Poliana, Duncan, William D., Galochkina, Zhanna, Zhang, Zhongyue, Kostewicz, Stephen H, Borobia, Manuel E, Lee, Ji-Hyun, Rogers, Sherise C.

“…e15549 Background: In recent years, multiple observational studies have suggested increased risk of developing gastrointestinal (GI) malignancies in patients…”
Get full text

The experience of first-year hematology and oncology fellows after implementing a wellness chief fellow at an academic cancer center by Rogers, Sherise C., Walker, Alison R., Otterson, Gregory Alan, Dettorre, Janet

“…Abstract only 11017 Background: Hematology & Oncology trainees are high risk for burnout. Risk factors include early stage in career, female gender and…”
Get full text

Randomized study to assess colonic microbiome changes in response to energy drink consumption (ROSANNA trial) by Jang, Tim, Kahramangil, Doga, Lee, Ji-Hyun, Kim, George P., Rogers, Sherise C., Sahin, Ilyas, Ramnaraign, Brian Hemendra, Terracina, Krista P., Nordenstam, Johan, Read, Thomas, Thomas, Ryan M., Yang, Ye, Jobin, Christian, George, Thomas J.

“…TPS3630 Background: Colorectal cancer (CRC), the second leading cause of cancer deaths in the US, is increasingly diagnosed in individuals under 50. This rise…”
Get full text

Storytelling as a means of improving community and decreasing burnout in a large academic cancer center by Rogers, Sherise C., Benson, Don M., Kraut, Eric H., Haque, Tamanna Zohra, Mousa, Luay, Fowler, Jeffery, Dettorre, Janet

“…Abstract only 11018 Background: Burnout is highly experienced amongst physicians who care for patients with cancer. Workplace isolation is a risk factor for…”
Get full text